Trial Profile
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 28 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 13 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.